ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib

G. Marisi, E. Petracci, F. Raimondi, L. Faloppi, F.G. Foschi, G. Lauletta, M. Iavarone, M. Canale, M. Valgiusti, L.M. Neri, P. Ulivi, G. Orsi, G. Rovesti, R. Vukotic, F. Conti, A. Cucchetti, G. Ercolani, K. Andrikou, S. Cascinu, M. ScartozziA. Casadei-Gardini

Research output: Contribution to journalArticle

Original languageItalian
JournalCancers
Volume11
Issue number7
DOIs
Publication statusPublished - 2019

Cite this

Marisi, G., Petracci, E., Raimondi, F., Faloppi, L., Foschi, F. G., Lauletta, G., Iavarone, M., Canale, M., Valgiusti, M., Neri, L. M., Ulivi, P., Orsi, G., Rovesti, G., Vukotic, R., Conti, F., Cucchetti, A., Ercolani, G., Andrikou, K., Cascinu, S., ... Casadei-Gardini, A. (2019). ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib. Cancers, 11(7). https://doi.org/10.3390/cancers11071023